GLG News by Ophthalmologists

Genentech should have voluntarily compared Lucentis with Avastin.All of Genentech's efforts to promote Lucentis seem self serving and insincere.

There has been a sea change in the treatment of postoperative cataract patients. The addition of a nonsteroidal has significantly reduced postoperative complications such as edema, discomfort and inflammation.Compliance with all medications is always an issue, and the use of a once daily medication...

This article describes the Phase II trial results of the PreView Scleral Implants (ReFocus Group Inc.) for the treatment of presbyopia.  Presbyopia is the natural age related loss of accommodation, or near focusing ability that leads to people wearing reading glasses. Scleral implants alter the...

AMO's acquisition of Intralase for $808 million has been seen by most financial industry analysts as positive.  Most financial analysts point to the improved diversification and strengthening of AMO's refractive portfolio which includes intraocular lenses, phacoemulsification equipment, VISX excimer...

It is reported today that AMO will purchase Intralase Corp for 808 million dollars in what could securely position AMO as the world leader in all aspects of LASIK and laser vision correction technology. For months it has been speculated that such a purchase would occur.

While the use of Intacs has practically ended for routine correction of myopia, and the company management and ownership has shifted several times in the last few years, there has been a great interest and success in using these implants for the stabilization of eyes with ectasias such as keratoconus...

This article describes the results of a "newer" refractive surgery technique known as sub-Bowman's keratomileusis or SBK.  SBK involves creating a corneal flap just below the epithelial layer of the cornea.  This flap is approximately 60-70 microns in thickness compared to a traditional...

Despite short term patient satisfaction for the correction of myopia, with the multiple problems and issues associated with the approval of the Visian ICL (phakic iol) for correction of myopia over the past several years, and some studies that indicated higher corneal endothelial cell count loss and...

While the authors caution that further studies are required to evaluate the safety and efficacy of Avastin, it is clear that there is a huge interest in this therapy for macular degenration due to its apparent effectivity and relative low cost in relation to other similar anti vgef therapies. ...

It is interesting to see that the government is analyzing the cost of correcting refractive errors in the USA across the entire population. While the military considers it cost effective and safe to offer refractive surgery to a large percentage of its active recruits at a minimal expense to the patient,...